Product Description
ASN008is a novel, topical Na+-channel blocker with high functional selectivity for itch and pain sensing neurons without affecting motor neurons.
Mechanisms of Action: Ion Channel Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Asana BioSciences
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic|Pruritus
Phase 1: Pruritus|Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05870865 |
ASN008-201 | P2 |
Completed |
Dermatitis, Atopic|Pruritus |
2023-11-27 |
21% |
2024-12-28 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT03798561 |
ASN008-101 | P1 |
Completed |
Dermatitis, Atopic|Pruritus |
2020-03-20 |
10% |
2023-02-26 |
Primary Endpoints|Treatments |